ASSIGNMENT AND ASSUMPTION OF EMPLOYMENT AGREEMENTAssignment and Assumption of Employment Agreement • March 31st, 2021 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 31st, 2021 Company Industry JurisdictionThis Assignment and Assumption (this “Agreement”) of Employment Agreement is made as of March 30, 2021 (the “Effective Date”), by and among Brooklyn ImmunoTherapeutics LLC, a Delaware limited liability company (“Assignor”), Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (“Assignee”), and Lynn Sadowski Mason (“Mason” and, collectively with Assignor and Assignee, the “Parties”).
ASSIGNMENT AND ASSUMPTION OF EMPLOYMENT AGREEMENTAssignment and Assumption of Employment Agreement • March 31st, 2021 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 31st, 2021 Company Industry JurisdictionThis Assignment and Assumption (this “Agreement”) of Employment Agreement is made as of March 30, 2021 (the “Effective Date”), by and among Brooklyn ImmunoTherapeutics LLC, a Delaware limited liability company (“Assignor”), Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (“Assignee”), and Ronald Guido (“Guido” and, collectively with Assignor and Assignee, the “Parties”).
AMENDED AND RESTATED ROYALTY AGREEMENT AND DISTRIBUTION AGREEMENTRoyalty Agreement • March 31st, 2021 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 31st, 2021 Company Industry JurisdictionThis Amended and Restated Royalty Agreement and Distribution Agreement (this “Agreement”) is entered into as of March 22, 2021 by and between Brooklyn Immunotherapeutics, LLC, a Delaware limited liability company with offices located at Brooklyn Army Terminal, 140 58th Street, Bldg. A, Suite 2100, Brooklyn, NY 11220 (the “Company”), Brooklyn Immunotherapeutics Investors GP LLC, a Delaware limited liability company (“Investors GP”), Brooklyn Immunotherapeutics Investors LP, a Delaware limited partnership (“Investors LP”), and the beneficiary parties listed on Schedule A (“the “Holders”). Each of the Company, Investors GP, Investors LP and the Holders are jointly referred to herein as the “Parties” and each, individually, as a “Party.”